Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LTRNNASDAQ:ONCYNASDAQ:ORGSNASDAQ:PLUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLTRNLantern Pharma$3.19+4.6%$3.43$2.55▼$6.40$34.40M1.6364,706 shs32,405 shsONCYOncolytics Biotech$0.34$0.52$0.33▼$1.53$29.38M1875,169 shs672,129 shsORGSOrgenesis$1.95+0.4%$2.25$0.87▼$10.80$9.35M0.729,234 shs1,480 shsPLURPluri$4.49+0.7%$4.59$3.33▼$7.13$35.17M0.7715,927 shs11,475 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLTRNLantern Pharma0.00%-8.51%-14.97%-18.87%-50.41%ONCYOncolytics Biotech0.00%-15.49%-35.71%-46.67%-66.95%ORGSOrgenesis0.00%+2.11%-21.77%-48.40%+193,999,900.00%PLURPluri0.00%-2.19%-8.79%-3.88%-27.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLTRNLantern Pharma2.0505 of 5 stars3.52.00.00.01.30.81.3ONCYOncolytics Biotech1.2279 of 5 stars3.42.00.00.01.70.00.0ORGSOrgenesisN/AN/AN/AN/AN/AN/AN/AN/APLURPluri1.7697 of 5 stars3.53.00.00.01.80.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLTRNLantern Pharma 3.00Buy$25.00683.70% UpsideONCYOncolytics Biotech 2.75Moderate Buy$4.331,174.51% UpsideORGSOrgenesis 0.00N/AN/AN/APLURPluri 3.00Buy$12.00167.26% UpsideCurrent Analyst Ratings BreakdownLatest ORGS, ONCY, PLUR, and LTRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025PLURPluriAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.005/21/2025ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/16/2025ONCYOncolytics BiotechJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/2/2025LTRNLantern PharmaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.003/10/2025ONCYOncolytics BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $3.003/10/2025ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/10/2025ONCYOncolytics BiotechRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$6.00 ➝ $5.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLTRNLantern PharmaN/AN/AN/AN/A$3.76 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/AORGSOrgenesis$662K14.12N/AN/A($6.58) per share-0.30PLURPluri$1.03M34.01N/AN/A($0.42) per share-10.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLTRNLantern Pharma-$15.96M-$1.84N/AN/AN/AN/A-56.91%-51.17%8/7/2025 (Estimated)ONCYOncolytics Biotech-$20.56M-$0.29N/AN/AN/AN/A-141.15%-84.73%7/30/2025 (Estimated)ORGSOrgenesis-$55.36MN/A0.00∞N/A-3,827.81%N/A-130.18%8/6/2025 (Estimated)PLURPluri-$20.89M-$5.53N/A∞N/A-3,551.49%-2,778.13%-83.61%N/ALatest ORGS, ONCY, PLUR, and LTRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025LTRNLantern Pharma-$0.49-$0.42+$0.07-$0.42N/AN/A5/14/2025Q1 2025ONCYOncolytics Biotech-$0.09-$0.06+$0.03-$0.06N/AN/A5/13/2025Q3 2025PLURPluriN/A-$0.94N/A-$0.94N/A$0.43 million3/27/2025Q4 2024LTRNLantern Pharma-$0.51-$0.54-$0.03-$0.54N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLTRNLantern PharmaN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/AORGSOrgenesisN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLTRNLantern PharmaN/A8.318.31ONCYOncolytics BiotechN/A2.992.99ORGSOrgenesisN/A0.070.07PLURPluri4.445.045.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLTRNLantern Pharma28.62%ONCYOncolytics Biotech6.82%ORGSOrgenesis22.56%PLURPluri16.59%Insider OwnershipCompanyInsider OwnershipLTRNLantern Pharma7.31%ONCYOncolytics Biotech0.10%ORGSOrgenesis5.66%PLURPluri10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLTRNLantern Pharma2010.79 million10.00 millionOptionableONCYOncolytics Biotech3086.42 million85.42 millionNot OptionableORGSOrgenesis1504.80 million4.53 millionNo DataPLURPluri1507.83 million6.28 millionOptionableORGS, ONCY, PLUR, and LTRN HeadlinesRecent News About These CompaniesPluri (NASDAQ:PLUR) Stock Price Up 0.2% - Should You Buy?May 29, 2025 | americanbankingnews.comPluri Inc. reschedules 2025 annual meetingMay 27, 2025 | investing.comBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical TrialsMay 27, 2025 | prnewswire.comContrasting CARGO Therapeutics (NASDAQ:CRGX) & Pluri (NASDAQ:PLUR)May 24, 2025 | americanbankingnews.comBrainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plansMay 19, 2025 | msn.comPluri Inc.: Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.May 16, 2025 | finanznachrichten.dePluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market ExpansionMay 16, 2025 | tmcnet.comPluri: Fiscal Q3 Earnings SnapshotMay 13, 2025 | timesunion.comPluri Inc. acquires majority stake in Kokomodo Ltd.April 30, 2025 | uk.investing.comPluri acquires 71% stake in KokomodoApril 29, 2025 | foodbusinessnews.netPluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.April 28, 2025 | globenewswire.comPluri Inc. enters agreement, issues pre-funded warrantsApril 27, 2025 | investing.comUkraine gains access to Israeli anti-radiation drug amid nuclear threatsApril 21, 2025 | msn.comUkraine prepares for nuclear emergency - Israel to help save thousandsApril 21, 2025 | msn.comIn case of a nuclear event, Ukraine to use Israeli placenta-based emergency treatmentApril 20, 2025 | msn.comInnovative Treatment Aims to Protect Ukrainians from Nuclear Radiation ThreatApril 17, 2025 | themunicheye.comPluri announces USPTO issued patent covering its immune cell expansion techApril 12, 2025 | markets.businessinsider.comPluri’s immune cell expansion technologies gain patentsApril 11, 2025 | finance.yahoo.comPluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and IsraelApril 10, 2025 | finance.yahoo.comUsing cell science to fight nuclear weapons: How is Pluri revolutionizing health and food tech?March 14, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeORGS, ONCY, PLUR, and LTRN Company DescriptionsLantern Pharma NASDAQ:LTRN$3.19 +0.14 (+4.59%) Closing price 03:57 PM EasternExtended Trading$3.19 0.00 (0.00%) As of 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Oncolytics Biotech NASDAQ:ONCY$0.34 +0.00 (+0.29%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Orgenesis NASDAQ:ORGS$1.95 +0.01 (+0.39%) As of 03:53 PM EasternOrgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.Pluri NASDAQ:PLUR$4.49 +0.03 (+0.67%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
